More MS news articles for Jan 2002

Glial toxicity in urine and multiple sclerosis|1454376537210543070/-1052814329/6/7051/7051/7052/7052/7051/-1

Multiple Sclerosis, December 2001, vol. 7, no. 6, pp. 383-388(6)
Malcus-Vocanson C. [1]; Giraud P. [2]; Micoud F. [1]; Janin V. [1]; Charles M.H. [1]; Broussolle E. [2]; Chazot G. [2]; Mandrand B. [1]; Perron H. [1] *
[1] bioMérieux-Pierre Fabre, 69280 Marcy L'Etoile, France [2] Department of Neurology D, Hôpital Neurologique Pierre Wertheimer, BP Lyon-Montchat, 69394 Lyon Cedex 03, France [*] Correspondence: CH Perron, bioMérieux Pierre-Fabre, R&D department, 69280 Marcy L'etoile, France


The biochemical and biological characterization of a cytotoxic activity targeting macroglial cells (oligodendrocytes and astrocytes), in moncyte cultures and in CSF of a patient with multiple sclerosis, has previously been described.

In further studies, cell-based tests have shown a good correlation between this glial cytotoxic (gliotoxic) activity, in CSF or in urine, and MS.

We now present results obtained with urine samples from 102 MS patients, 51 patients with other neurological disease and 35 healthy subjects using a bioassay set up for the detection of an apoptosis-like effect induced in a glial cell-line.

Significant gliotoxicity was detected in urine from 74/102 MS patients while only 4/51 neurological controls (P>0.001) and never in healthy subjects (P>0.001).

Given the statistical tendency provided by this bioassay and its technical limitations for routine testing, it is now used for monitoring the molecular characterization of this 'gliotoxic factor'. Its replacement by a specific immunoassay could provide more accurate routine techniques for the detection of this biological marker in MS.

© 2002 ingenta